Immunogenicity and Safety of GSK Biologicals' (Pre-) Pandemic Influenza Candidate Vaccine

PHASE2CompletedINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

September 1, 2008

Primary Completion Date

March 7, 2009

Study Completion Date

March 7, 2009

Conditions

Influenza

Interventions

BIOLOGICAL

Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted

All subjects will receive 2 doses administered as an intramuscular (IM) injection.

Trial Locations (2)

GSK Investigational Site, Fukuoka

GSK Investigational Site, Tokyo